Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07496567 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
A Phase 2 study, sponsored by EyeBiotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 960
- Enrollment target
NCT07496567 is a Phase 2 study that is actively recruiting participants, run by EyeBiotech. The registered enrollment target is 960 participants.
The verdict
NCT07496567, a Phase 2 study, is actively recruiting participants, sponsored by EyeBiotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 960 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Interventions
- DRUG Aflibercept
- DRUG Tiespectus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07496567
The ClinicalTrials.gov registry entry for NCT07496567 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyeBiotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aflibercept is the first listed.
NCT07496567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07496567 about?
NCT07496567 is a clinical study titled "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)". Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) ca...
What is the current status of trial NCT07496567?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 960 participants. The study started on 2026-04-15. Estimated completion is 2028-07-31.
What interventions are being tested in trial NCT07496567?
The interventions under investigation include: Aflibercept (DRUG), Tiespectus (DRUG).
Who is sponsoring clinical trial NCT07496567?
This trial is sponsored by EyeBiotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.